Open-label Study of Curcumin C-3 Complex in Schizophrenia
Keywords
Abstract
Description
Detailed Description: The overall objective of the study was to evaluate whether the standardized proprietary formulation of curcumin [Super Curcumin@ :C-3 Complex@ with Bioperine@) manufactured by American Finest Inc. NJ USA ] extracted from the curry plant (Curcuma Longata) , can improve the negative symptoms and cognitive impairments in patients diagnosed as schizophrenia and to determine the response rate in negative symptoms at 16 weeks. Response rate was defined as the positive change of minimum 30% or higher from baseline to the score measured at 16 weeks. Negative symptoms refer to the cluster of symptoms of apathy, alogia, blunted affect and lack of motivation affecting severely the ways the individual functions in the community at large. In the study, the investigators proposed to test the hypothesize that Super curcumin@ is efficacious and safe when combined with standard antipsychotic drugs in the cohort of patients diagnosed as schizophrenia. Throughout the study, the proprietary product(Super curcumin@) was used. Supercurcumin@ consisted of the primary medicinally active ingredient, Curcumin C-3 Complex, in combination with Bioperine@, the metabolic enhancer extracted from black pepper, in order to increase the systemic bioavailability of curcumin C-3 complex. For the oral formulation of Super- curcumin@: 1 gm-capsule has 1 gm of curcumin C-3 complex and 5 mg of Bioperine@ . The study protocol consisted of recruiting subjects with diagnosed as schizophrenia who would be receiving either 1 gm or 4 gm of Super-Curcumin@ given orally once daily for 16 weeks, on negative symptoms and cognition. For assessing the safety and tolerability of Supercurcumin@ , the study protocol required that the patients would be monitored regularly for vital signs:blood pressure, pulse,body weight, routine blood chemistry and comprehensive adverse events profile (Treatment Emergent Adverse Events checklist) including the AIMS (Abnormal Involuntary Movement Scale). At baseline and at regular intervals throughout the 16-week treatment period, standardized measures of negative and positive symptoms and neurocognition would be administered to examine the efficacy of Curcumin C-3 complex in schizophrenia. For analysing the results, within-subject pre- and post-treatment responses would be subject to statistical procedures to evaluate whether Super-Curcumin@ can ameliorate the persistent negative symptoms and cognitive deficits in schizophrenia.
Dates
| Last Verified: | 03/31/2013 |
| First Submitted: | 06/03/2013 |
| Estimated Enrollment Submitted: | 06/08/2013 |
| First Posted: | 06/11/2013 |
| Last Update Submitted: | 06/08/2013 |
| Last Update Posted: | 06/11/2013 |
| Actual Study Start Date: | 05/31/2009 |
| Estimated Primary Completion Date: | 09/30/2011 |
| Estimated Study Completion Date: | 04/30/2012 |
Condition or disease
Intervention/treatment
Dietary Supplement: Supercurcumin
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Supercurcumin The study protocol stipulates that subjects diagnosed as DSM IV-TR (Diagnostic Statistical Manual IV-Transitional Revised) would be receiving either 1 gm Super-Curcumin@ capsule once daily or 4 gm Super-Curcumin@ once daily for a total of 16 weeks. Super-Curcumin@ in capsule form is a patented formulation of curcumin certified by Sabinsa Corp.NJ USA and produced by America's Finest Inc. 1 gm-capsule Super-Curcumin@ consist of 1 gm Curcumin C-3 complex and 5 mg of Bioperine. | Dietary Supplement: Supercurcumin The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Male or female: - DSMIV (Diagnostic Statistical Manual -TR version) Schizophrenia - Male or Female , - age 18-65 yrs - SANS (Scale of Negative Symptoms of Schizophrenia ) > 30 - Stable antipsychotic dosage at least 1 month Exclusion Criteria: - Current Substance use Disorder except Nicotine dependence - Regular Use of NSAID (non-steroidal anti-inflammatory drugs) - cancer History - Recent myocardial infarction - Unstable angina, - untreated or severe hypertension - Poorly controlled diabetes mellitus Type I or Type II - Chronic liver & gallbladder diseases - Recent GERD (Gastroesophageal Reflux Disorder) - Pregnancy and breast-fed. - Allergic reaction to Curcumin - Neurological disorders: epilepsy, stroke - Hamilton Depression Scale Hamilton Depression Rating Scale( HAM-D-17 item) > 24 - |
Outcome
Primary Outcome Measures
1. Negative Symptoms [Change from baseline Negative symptom at 16 weeks]
Secondary Outcome Measures
1. Neurocognition measures [Change from Baseline neurocognitive measures at 16 weeks]
2. Positive symptoms [Change from Basline Positive symptoms at 16 weeks]
3. General psychopathology [Change from baseline general psychopathology at 16 weeks]
